Fluridil, A Rationally Designed Topical Agent For Androgenetic Alopecia: First Clinical Experience

August 2002 in “ Dermatologic Surgery ”

Milos Sovak, Allen L. Seligson, Renata Kucerova, Marie Bienova, Marian Hajduch, Milan Buček

fluridil androgenetic alopecia anagen:telogen ratio hirsutism AGA

Studysummary This study found that topical fluridil increased the anagen hair percentage in men with androgenetic alopecia without causing irritation or systemic absorption over 9 months.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study evaluated the safety and efficacy of topical fluridil in treating androgenetic alopecia (AGA) in men. The study found that fluridil is safe, non-irritating, and effective in promoting hair growth by increasing the anagen:telogen ratio. The increased ratio was achieved within the first 3 months and remained for 9 months, making fluridil a promising agent for the management of incipient or recent male AGA. However, further studies are needed to assess fluridil's safety and effectiveness in female AGA and hirsutism.

View this study on journals.lww.com →

Discuss this study in the Community →

Research cited in this study

9 / 9 results

research Changes in Hair Weight and Hair Count in Men with Androgenetic Alopecia After Treatment with Finasteride, 1 mg, Daily

66 citations , April 2002 in “Journal of The American Academy of Dermatology”

In this study, finasteride, 1 mg daily, significantly increased hair weight more than hair count in men with androgenetic alopecia, indicating additional factors like hair growth rate and thickness may contribute to its effectiveness.

research New Topical Antiandrogenic Formulations Can Stimulate Hair Growth in Human Bald Scalp Grafted Onto Mice

37 citations , January 2000 in “International Journal of Pharmaceutics”

In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.

Changes in Hair Weight and Hair Count in Men with Androgenetic Alopecia After Application of 5% and 2% Topical Minoxidil, Placebo, or No Treatment

research Changes in Hair Weight and Hair Count in Men with Androgenetic Alopecia After Application of 5% and 2% Topical Minoxidil, Placebo, or No Treatment

115 citations , November 1999 in “Journal of The American Academy of Dermatology”

In this study, men using 2% and 5% minoxidil solutions experienced a significant increase in hair weight for 96 weeks compared to placebo, with effects diminishing after treatment cessation.

research Treatment of Hair Loss

370 citations , September 1999 in “The New England Journal of Medicine”

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

A Controlled Study of the Effects of RU58841, a Non-Steroidal Antiandrogen, on Human Hair Production by Balding Scalp Grafts Maintained on Testosterone-Conditioned Nude Mice

research A Controlled Study of the Effects of RU58841, a Non-Steroidal Antiandrogen, on Human Hair Production by Balding Scalp Grafts Maintained on Testosterone-Conditioned Nude Mice

10 citations , November 1997 in “British Journal of Dermatology”

This study found that the non-steroidal antiandrogen RU58841 increased hair growth rates and promoted hair cycle initiation in balding human scalp grafts on testosterone-conditioned nude mice, indicating a positive effect on hair growth.

Preliminary Pharmacokinetics and Metabolism of Novel Non-Steroidal Antiandrogens in the Rat: Relation of Their Systemic Activity to the Formation of a Common Metabolite

research Preliminary Pharmacokinetics and Metabolism of Novel Non-Steroidal Antiandrogens in the Rat: Relation of Their Systemic Activity to the Formation of a Common Metabolite

16 citations , October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology”

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

research RU 58841, A New Specific Topical Antiandrogen: A Candidate of Choice for the Treatment of Acne, Androgenetic Alopecia, and Hirsutism

49 citations , January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology”

This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.

research The Antiandrogens

19 citations , January 1993 in “Dermatologic Clinics”

research The Inheritance Of Common Baldness: To Be Or Not To Be?

203 citations , November 1984 in “Journal of the American Academy of Dermatology”

This study presents evidence suggesting that androgenetic alopecia is most likely inherited through a polygenic model, challenging the traditional view that it is caused by a simple Mendelian autosomal dominant gene.